Abstract:In an October 28, 2011, Federal Register notice, the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer announced the initiation of "Translation of Nanotechnology in Cancer" (TONIC), a public private industry partnership intended to promote translational research and development opportunities of nanotechnology-based cancer solutions.

In an October 28, 2011, Federal Register notice, the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer announced the initiation of "Translation of Nanotechnology in Cancer" (TONIC), a public private industry partnership intended to promote translational research and development opportunities of nanotechnology-based cancer solutions. The notice states that an immediate consequence of this effort is the formation of a consortium involving government and pharmaceutical and biotechnology companies. The consortium will evaluate "promising nanotechnology platforms and facilitate their successful translation from academic research to clinical environment, resulting in safe, timely, effective and novel diagnosis and treatment options for cancer patients." According to the notice, membership in the TONIC consortium will be limited to companies that: (1) have a successful track record of translating diagnostics and drug formulations and reaching their regulatory approval; and (2) are engaged in the development of nanotechnology-based formulations with application to imaging, diagnostics, and therapy.